false
0001555279
0001555279
2024-08-06
2024-08-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13
or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event
Reported): August 6, 2024
908 Devices Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-39815 |
|
45-4524096 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
645
Summer Street
Boston,
MA
02210
(Address
of principal executive offices, including zip code)
(857)
254-1500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each
class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
Common Stock, par value $0.001 per share |
MASS |
The NASDAQ Global Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 ( §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item
2.02 |
Results of Operations and Financial Condition. |
On August 6, 2024, 908 Devices Inc. (“908 Devices”)
announced its financial results for the second quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1
to this Report on Form 8-K.
The information contained in Item 2.02 of this Current Report on Form 8-K
is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be
incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the
Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
|
|
(d) Exhibits: |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 6, 2024 |
908 Devices Inc. |
|
|
|
By: |
/s/ Michael S. Turner |
|
|
Name: Michael S. Turner |
|
|
Title: Chief Legal and Administrative Officer |
Exhibit 99.1
![Logo
Description automatically generated](https://www.sec.gov/Archives/edgar/data/1555279/000110465924086090/tm2420867d1_ex99-1img001.jpg)
908 Devices Reports Second Quarter 2024 Financial
Results and Reiterates 2024 Revenue Outlook
Revenue increases 16% compared to prior year,
driven by newly acquired handheld products
BOSTON – August 6, 2024 –
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial
results for the quarter ended June 30, 2024.
"We delivered solid execution on a multitude of fronts in the
quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are
now supporting both our new and existing forensics customers more efficiently,” said Kevin J. Knopp, CEO and Co-founder. “We
also maintained a strong focus on operational excellence during the quarter and have begun to see early benefits of our increasing scale.”
Recent Highlights
● | Revenue of $14.0 million for the second quarter 2024, increasing
16% compared to the second quarter 2023 |
| o | Handheld
revenue was $11.1 million, increasing 26% year over year |
| o | Desktop
revenue was $2.9 million, decreasing 9% year over year |
| o | Recurring
revenue was $5.3 million, increasing 33% year over year |
| o | 38%
of revenue was recurring revenue, driven by service and REBEL consumables |
● | Gross margin increased 490 basis points to 53% for the second quarter
2024, partly due to timing of production but also as a result of scale across the business
including higher handheld service revenues |
● | Launched a quantification package that enhances our XplorIR handheld
gas and vapor analyzer, enabling first responders to now identify and quantify nearly 5,000
airborne chemicals |
● | Completed the commercial integration of RedWave Technology |
● | Presented 13 posters at the American Society for Mass Spectrometry
(ASMS) conference and were collaborators on three oral presentations with researchers from
the University of Wisconsin-Madison and the National Institute for Bioprocessing Research
and Training (NIBRT) |
● | Appointed Michele M. Leonhart, former administrator of the U.S. Drug
Enforcement Administration, to our Board of Directors |
Second Quarter 2024 Financial Results
Revenue was $14.0 million for the three months
ended June 30, 2024, a 16% increase over the prior year period. This was primarily driven by an increase in handheld devices revenue
offset by a decrease in desktop devices revenue. The installed base grew to 3,067 devices with 143 handheld devices and 10 desktop devices
placed during the second quarter 2024. Recurring revenue represented 38% of total revenues in the quarter.
Gross profit was $7.4 million for the second quarter of 2024, compared
to $5.8 million for the corresponding period in the prior year. Gross margin was 53% as compared to 48% for the corresponding prior year
period. Adjusted gross profit was $8.1 million for the second quarter of 2024, compared to $6.0 million for the corresponding period
in the prior year. Adjusted gross margin was 58% as compared to 50% for the corresponding prior year period.
Operating expenses were $21.0 million for the
second quarter of 2024, compared to $16.7 million for the corresponding prior year period. This increase was driven by $1.9 million in
acquisition and integration costs, the inclusion of two months of operating expenses related to our RedWave acquisition, and stock-based
compensation.
Net loss was $12.5 million for the second quarter
of 2024, compared to $9.3 million for the corresponding prior year period. Adjusted EBITDA was a loss of $7.3 million for the second
quarter of 2024, compared to a loss of $7.7 million for the second quarter of 2023.
Cash, cash equivalents and marketable securities were $77.4 million
as of June 30, 2024 with no debt outstanding.
2024 Guidance
908 Devices continues to expect full year reported
2024 revenue to be in the range of $63.0 million to $65.0 million, representing 25% to 29% growth over full year 2023. This includes
$11 million of expected revenue from RedWave Technology, representing 8 months of ownership.
Webcast Information
908 Devices will host a conference call to discuss the second quarter
2024 financial results before market open on Tuesday, August 6, 2024 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of
the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available
for replay for at least 90 days after the event.
About 908 Devices
908 Devices
is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s
devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly
address some of the most critical problems in forensics, bioprocessing, pharma / biopharma, life sciences research and adjacent markets.
The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power
of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.
Non-GAAP Measures of Financial Performance
To supplement
the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the
following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable
GAAP financial results in the tables below:
| ● | Adjusted
Gross Profit is defined as gross profit excluding intangible amortization, acquisition and
integration costs, restructuring charges (including the costs of severance), and non-cash
expenses related to stock-based compensation. |
| ● | Adjusted
Gross Margin is defined as Adjusted Gross Profit expressed as a percentage of total revenue. |
| ● | Adjusted
EBITDA is defined as net loss excluding other income, benefit for income taxes, depreciation,
intangible amortization, acquisition and integration costs, restructuring charges (including
the costs of severance), non-cash expenses related to stock-based compensation, and costs
associated with contingent consideration related to the Company’s acquisitions and
for which the conditions for payment have not yet been achieved. |
The Company’s
non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation
to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the
period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing
operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However,
as there are no standardized methods of calculating these non-GAAP financial measures, the Company’s methods may differ from those
used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures
used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations
since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results.
Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in
isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company
believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide
investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between
periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s
business.
Forward Looking Statements
This press release includes “forward looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of
historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue
and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,”
“estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s
current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially
from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors”
and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make
from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable,
it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking
statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
Investor Contact:
Carrie Mendivil
IR@908devices.com
Media Contact:
Barbara Russo
brusso@908devices.com
908 DEVICES INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Revenue: | |
| | |
| | |
| | |
| |
Product revenue | |
$ | 10,266 | | |
$ | 9,595 | | |
$ | 17,499 | | |
$ | 16,617 | |
Service revenue | |
| 3,681 | | |
| 2,354 | | |
| 6,439 | | |
| 4,594 | |
Contract revenue | |
| 100 | | |
| 145 | | |
| 100 | | |
| 370 | |
Total revenue | |
| 14,047 | | |
| 12,094 | | |
| 24,038 | | |
| 21,581 | |
Cost of revenue: | |
| | | |
| | | |
| | | |
| | |
Product cost of revenue | |
| 4,732 | | |
| 4,800 | | |
| 7,942 | | |
| 8,586 | |
Service cost of revenue | |
| 1,823 | | |
| 1,448 | | |
| 3,601 | | |
| 2,718 | |
Contract cost of revenue | |
| 74 | | |
| 52 | | |
| 74 | | |
| 99 | |
Total cost of revenue | |
| 6,629 | | |
| 6,300 | | |
| 11,617 | | |
| 11,403 | |
Gross profit | |
| 7,418 | | |
| 5,794 | | |
| 12,421 | | |
| 10,178 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 6,381 | | |
| 5,525 | | |
| 12,171 | | |
| 10,923 | |
Selling, general and administrative | |
| 14,597 | | |
| 11,208 | | |
| 26,498 | | |
| 23,211 | |
Total operating expenses | |
| 20,978 | | |
| 16,733 | | |
| 38,669 | | |
| 34,134 | |
Loss from operations | |
| (13,560 | ) | |
| (10,939 | ) | |
| (26,248 | ) | |
| (23,956 | ) |
Other income, net | |
| 943 | | |
| 1,522 | | |
| 2,644 | | |
| 1,955 | |
Loss from operations before income taxes | |
| (12,617 | ) | |
| (9,417 | ) | |
| (23,604 | ) | |
| (22,001 | ) |
Benefit for income taxes | |
| 69 | | |
| 71 | | |
| 139 | | |
| 122 | |
Net loss | |
$ | (12,548 | ) | |
$ | (9,346 | ) | |
$ | (23,465 | ) | |
$ | (21,879 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per share attributable to common stockholders | |
$ | (0.37 | ) | |
$ | (0.29 | ) | |
$ | (0.70 | ) | |
$ | (0.68 | ) |
Weighted average common shares outstanding | |
| 34,061,933 | | |
| 32,199,156 | | |
| 33,386,413 | | |
| 32,083,122 | |
908 DEVICES INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
| |
June 30, | | |
December 31, | |
| |
2024 | | |
2023 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash, cash equivalents and marketable securities | |
$ | 77,383 | | |
$ | 145,682 | |
Accounts receivable, net | |
| 10,987 | | |
| 8,989 | |
Inventory | |
| 18,589 | | |
| 14,938 | |
Prepaid expenses and other current assets | |
| 3,485 | | |
| 4,181 | |
Total current assets | |
| 110,444 | | |
| 173,790 | |
Operating lease, right-of-use assets | |
| 5,904 | | |
| 6,233 | |
Property and equipment, net | |
| 3,556 | | |
| 3,342 | |
Goodwill | |
| 40,220 | | |
| 10,367 | |
Intangible, net | |
| 47,298 | | |
| 7,860 | |
Other long-term assets | |
| 1,352 | | |
| 1,389 | |
Total assets | |
$ | 208,774 | | |
$ | 202,981 | |
Liabilities and Stockholders' Equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 7,610 | | |
$ | 9,904 | |
Deferred revenue | |
| 11,954 | | |
| 10,629 | |
Operating lease liabilities | |
| 2,153 | | |
| 2,016 | |
Total current liabilities | |
| 21,717 | | |
| 22,549 | |
Deferred revenue, net of current portion | |
| 9,528 | | |
| 3,929 | |
Other long-term liabilities | |
| 21,170 | | |
| 11,012 | |
Total liabilities | |
| 52,415 | | |
| 37,490 | |
Total stockholders' equity | |
| 156,359 | | |
| 165,491 | |
Total liabilities and stockholders' equity | |
$ | 208,774 | | |
$ | 202,981 | |
908 DEVICES INC.
Reconciliations of GAAP to Non-GAAP Financial
Measures
(Unaudited, amounts in thousands, except percentage
and per share data)
In all tables below, totals may not add due
to rounding
Reconciliation from Gross Profit (GAAP) to
Adjusted Gross Profit (Non-GAAP) and Margin Percentage:
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Gross Profit (GAAP) | |
$ | 7,418 | | |
$ | 5,794 | | |
$ | 12,421 | | |
$ | 10,178 | |
| |
| | | |
| | | |
| | | |
| | |
Intangible amortization | |
| 530 | | |
| 107 | | |
| 637 | | |
| 213 | |
Acquisition and integration costs | |
| - | | |
| - | | |
| - | | |
| - | |
Restructuring | |
| - | | |
| - | | |
| - | | |
| - | |
Stock-based compensation | |
| 202 | | |
| 140 | | |
| 373 | | |
| 255 | |
| |
| | | |
| | | |
| | | |
| | |
Adjusted Gross Profit (Non-GAAP) | |
$ | 8,150 | | |
$ | 6,041 | | |
$ | 13,431 | | |
$ | 10,646 | |
| |
| | | |
| | | |
| | | |
| | |
Gross Margin Percentage (GAAP) | |
| 53 | % | |
| 48 | % | |
| 52 | % | |
| 47 | % |
| |
| | | |
| | | |
| | | |
| | |
Adjusted Gross Margin Percentage (Non-GAAP) | |
| 58 | % | |
| 50 | % | |
| 56 | % | |
| 49 | % |
Reconciliation from Net Loss (GAAP) to Adjusted
EBITDA (Non-GAAP):
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
Net Loss (GAAP) | |
$ | (12,548 | ) | |
$ | (9,346 | ) | |
$ | (23,465 | ) | |
$ | (21,879 | ) |
| |
| | | |
| | | |
| | | |
| | |
Adjustments: | |
| | | |
| | | |
| | | |
| | |
Other income, net | |
| (943 | ) | |
| (1,522 | ) | |
| (2,644 | ) | |
| (1,955 | ) |
Benefit for income taxes | |
| (69 | ) | |
| (71 | ) | |
| (139 | ) | |
| (122 | ) |
Depreciation | |
| 500 | | |
| 368 | | |
| 918 | | |
| 738 | |
Intangible amortization | |
| 693 | | |
| 219 | | |
| 913 | | |
| 437 | |
Acquisition and integration costs | |
| 1,950 | | |
| - | | |
| 1,950 | | |
| - | |
Restructuring | |
| - | | |
| - | | |
| - | | |
| 524 | |
Stock-based compensation | |
| 3,096 | | |
| 2,578 | | |
| 5,739 | | |
| 4,744 | |
Contingent consideration | |
| - | | |
| 65 | | |
| - | | |
| 230 | |
| |
| | | |
| | | |
| | | |
| | |
Adjusted EBITDA (Non-GAAP) | |
$ | (7,321 | ) | |
$ | (7,709 | ) | |
$ | (16,728 | ) | |
$ | (17,283 | ) |
v3.24.2.u1
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
908 Devices (NASDAQ:MASS)
過去 株価チャート
から 8 2024 まで 9 2024
908 Devices (NASDAQ:MASS)
過去 株価チャート
から 9 2023 まで 9 2024